Full field research on the competitor set Ledisa already bids on (taken from the account's own conquest ad groups), plus category leaders. Every fact is labeled: OBSERVED seen directly on a page during this research · INFERRED reasonable conclusion from observed signals · UNVERIFIED third-party claim we could not confirm. Nothing is invented; where a number could not be verified (e.g. Meta ad counts), we say so.
"Daily Wellness Patches for a Balanced Lifestyle." Hero = GLP-1 Patches at $42.95, listed ahead of NAD+, Sleep and Dopamine. Site-wide "50% OFF Sale is Live!" banner. No review counts or compliance disclaimers visible on the homepage.
Advertorial funnel — ads land on myhealthyshape.com presell pages; $150K+ per 90 days on competitor-brand conquesting, led by Kind Patches. Conquest economics on the Search page.
OBSERVED A telehealth-affiliated comparison article (pandameds.com) groups "Oceaura/Ledisa" and reports "1.9★ ratings; refund complaints." UNVERIFIED whether 1.9★ is accurate — but Ledisa is already being named in negative third-party review content.
The category leader, decisively. Renamed its hero to "Berberine Patches (Upgraded GLP-1)" — soft claims ("supports weight loss journey", "appetite control") wrapped in a 12-SKU lifestyle brand. $15/pack (subscription $12.75), Buy-2-Get-1 + 50% bundles. On-site: 4.65★/2,737 reviews, "Over 4 Million Happy Customers", press logos (Vogue, Forbes). Retail claims: CVS, Ulta, Target, Walmart — Bloomingdale's and Ulta product pages verified live. TikTok Shop: 364K+ single-pack sales (Media Matters, Sep 2025). Normal Shopify store — no advertorial funnel; converts on brand strength, price and retail validation. Also sells a compliant "GLP-1 Companion System" for people on prescription GLP-1s. INFERRED Ledisa cannot win a bare price/spec comparison ($42.95 vs $15) — its conquest clicks only convert through the advertorial preframe.
GLP-1 PDP at $79.99→$39.99 (50% off) with every variant sold out or unavailable; homepage pivoted to "Slim Control Patch" with GLP-1 terminology stripped entirely; "Trusted By Thousands" with no review counts. INFERRED a brand shrinking, repositioning or winding down. But note: the Triple Whale cross-check (Search page) shows Ledisa's Patched conquest converting at 2.32 ROAS today — dying brands leave orphaned demand that's cheap to pick up. Watch the volume trend, keep the line while it pays.
"Berberine Patches (formerly GLP-1 Patches)" — same rename move. Claims: "curbs cravings… consistent weight loss progress." Promo: stale "Spring Clearance – Buy 3 Get 2 Free" (observed in June); 70% off advertised in search results. 4.7★/869 on-site. Heavy brand-seeded PR footprint: AccessNewswire releases syndicated to Yahoo Finance, plus "scam or legit?" affiliate videos. INFERRED Ledisa's closest playbook peer (funnel subdomain, deep discounts, seeded PR) — no retail moat.
Soft "plant-based daily balance" positioning, ~$31, 4.3★/"8,658+" claimed. OBSERVED a network of 5+ additional "Official Website" clone domains plus Yahoo advertorials, and ~17 active Meta ads run by white-label pages ("Green Roots", "Decota") started Jun 8–10, 2026. INFERRED affiliate churn-and-burn operation; demand for "purisaki" searches is real, the entity behind it is unstable — its confused searchers ("is purisaki legit") are winnable.
The most aggressive claims in the set: "Reactivate GLP-1 naturally", "Targets stubborn fat while you sleep — no diet or exercise needed", anchored against "$1,300/month injections". Stale "FALL SALE 70% OFF" in June; 4.8★ with no review count; no ingredients listed, no FDA disclaimer found; checkout leaves the domain to a third-party platform. 6+ clone "official" domains; the same operator also runs "Lean Patch" — including attack funnels against its own other brand. INFERRED the segment most likely to be enforced out of existence; its keywords also carry drug-term policy risk for anyone bidding on them (Ledisa spends on both lines).
"The daily patch that fixes your broken hunger signals", "+13% GLP-1 production, clinically proven" (no study cited). Claimed 4.8★ from 24,748 reviews — UNVERIFIED, largest claimed count in the set. Fake-scarcity stack: 24-hour countdown, "SOLD OUT 6 TIMES", "Final Restock Until February 2026" — internally incoherent when read in June 2026 (stale hardcoded scarcity). OBSERVED parasite SEO at scale: Lipovia "review" pages injected into princeton.edu, stanford.edu, ctcd.edu and gatech.edu URLs. INFERRED pure funnel operator with legally exposed claims.
Mainstream "plant-powered wearable wellness" (B12, sleep, stress, hemp), $12–16, "10,000+ five-star reviews", strong retail. No GLP-1 or weight-loss SKU found. Not a competitor for the hero product — but it owns the shelf Ledisa's Sleep/Dopamine/NAD+ side catalog would compete on.
| Brand | What they are | Relevance for Ledisa |
|---|---|---|
| Barrière (mybarriere.com) | Design-led vitamin patches. Press coverage (CNBC/Retail Brew, May 2026): 600 → 6,000+ retail doors in a year, launching in 1,700 Walmart stores, ~$13–18/pack, projecting $10M 2026 revenue. No weight-loss patch. | Not a GLP-1 competitor — but living proof the retail-first, design-led patch model scales. The strategic counter-example to the funnel model. |
| NUTRIPATCH | "#1 Selling Vitamin Patches" (on-site claim). Nutrient patches via Amazon/Walmart/bariatric stores. | Not GLP-1 positioned. Low conquest value. |
| PatchAid (in Ledisa's conquest list, minor spend) | Bariatric-channel patch company. Runs a "GLP-1 Support" collection positioned for people taking GLP-1 medications + a "Berberine Patch (Natural GLP-1)". | Intent mismatch: its searchers are mostly on prescription GLP-1s looking for support, not for alternatives. Conquest copy promising an alternative won't convert them — build a companion-style message/SKU or drop the line. |
Top organic results: Superdrug, HealthCentral, Today.com ("Do They Work? Doctors Weigh In"), Baptist Health. No brand site ranks. Anyone researching hits a wall of "no FDA approval / placebo" content — which is exactly why the category routes cold traffic through advertorials.
Same skeptical layer plus parasite-SEO interlopers (a gatech.edu page ranking mid-page). Telehealth/prescription players (Midi, Superdrug) publish anti-patch content that converts patch-curious demand into prescription funnels — the real "reviews" competitors are telehealth brands monetizing doubt.
Kind Patches product pages rank 1–2; PatchMD runs a comparison page against Kind; Amazon listings follow. Ledisa is absent. This is the SERP the berberine advertorial strategy (Search page) buys into cheaply.
(1) Brand-seeded newswire advertorials syndicated to Yahoo Finance (Gentle, Purisaki, Ozempatch). (2) Parasite SEO on .edu domains (Lipovia). No Ledisa-owned content was observed ranking on any tested query.
OBSERVED (Media Matters, Sep 2025): GLP-1 patches "exploding" on TikTok Shop; Kind at 364K+ single-pack sales despite TikTok policy formally forbidding weight-management supplement claims — an enforcement gap and a platform-risk overhang for the whole category.
OBSERVED The direct GLP-1/berberine patch brands (Purisaki, Lipovia, Ozempatch, Gentle, Patched) have no brand-owned channel — their YouTube layer is affiliate "scam or legit?" reviews and skeptic content. The exception is Kind Patches (US + UK brand channels with sponsored Shorts). Adjacent wellness-patch brands (The Good Patch, Barrière, Nutri-Patch, Klova) also run channels. UNVERIFIED whether any rival runs paid YouTube/Demand Gen video ads — check the Ad Transparency Center per domain. Still the clearest opening for owned video (Demand Gen page).
Per-brand active-ad counts were not reliably retrievable (keyword pollution; page-level queries inconsistent) — so no counts are claimed beyond what was directly observed: ≥1 active Kind ad (bundle-led, soft claims), ~17 Purisaki ads via white-label pages, essentially nothing from Gentle's own page.
OBSERVED The one active ad matching "gentle patches" in the Meta Ad Library is from Jennings & Earley PLLC (running since May 28, 2026 · landing: claims.jefirm.com/dopamine-patch/, verified live): "Did you purchase dopamine patches marketed to improve focus, motivation, mood, or dopamine support? A consumer investigation is reviewing allegations that certain products may not perform as advertised… Compensation may be available." The plaintiff bar is actively recruiting wellness-patch consumers — and Ledisa sells a Dopamine patch.
| Authority | What happened (last 12 months) | Evidence |
|---|---|---|
| FDA | Public position: "There are no FDA-approved GLP-1 patches" and no approved berberine drug products. Sep 2025: 55+ warning letters to compounded-GLP-1 sellers. Feb 2026: 30 more to telehealth companies. No letter addressed to a patch brand yet (absence noted honestly) — but GLP-1 marketing is an active enforcement priority, and the Kind/Gentle/Patched renames suggest operators expect patches to be next. | OBSERVED |
| FTC | Dec 2025: final order against NextMed over deceptive GLP-1 weight-loss advertising. Weight loss is a standing FTC priority; "no diet or exercise needed" claims (running today on Ozempatch) are textbook prohibited language. | OBSERVED |
| Press | Today.com, Rolling Stone, Media Matters, HealthCentral all ran critical GLP-1-patch coverage; endocrinologist quote that studied doses are "8,000 times" what a patch contains; consumer reports of skin reactions. | OBSERVED |
| Plaintiff bar | Jennings & Earley consumer investigation into dopamine-patch claims, recruiting via Meta ads since May 28, 2026. | OBSERVED |
| Google Ads policy | Weight-loss supplements allowed but restricted: no equivalence to prescription drugs; no "miracle" claims; personalized-ad limits on weight-loss remarketing; Restricted Drug Terms gates semaglutide-adjacent keywords. Implications for Ledisa: the advertorial hop is exposed to bridge-page/misleading-content policy; Ozempatch/Nano conquest keywords carry disproportionate risk; "natural Ozempic" copy is suspension-grade. | OBSERVED policy · INFERRED implications |
This is a compliance-fragile category where the leaders have already repositioned away from "GLP-1" naming. Any growth plan that does not include claim hygiene, destination-policy cleanup and a naming de-risk should be considered structurally exposed. Ledisa still leads with "GLP-1" on its site, its feed titles and its ads.
TikTok (Kind + influencers) creates category demand; Google captures it. Every funnel brand — Gentle, Purisaki, Lipovia, Ozempatch, and Ledisa itself — is demand-capture riding on Kind's and TikTok's demand creation. Whoever builds owned demand creation (video, retail, community) escapes the knife fight.
Every funnel competitor uses fake scarcity, clone domains and unverifiable review counts — and the entire editorial layer screams scam. Nobody owns credible proof: a verified review profile, transparent per-patch dosing, real guarantee terms. The first funnel brand to look trustworthy wins the comparison layer the skeptic SERP creates. (This powers the Reviews landing proposal on the Search page.)
Kind, Gentle and Patched already de-risked their naming. Following protects the Google accounts and opens the less-saturated "berberine patch" SERP where only Kind ranks today.
Kind and PatchAid already monetize support products for people ON prescription GLP-1s — the largest adjacent honest market, and the one weight-adjacent positioning regulators aren't hostile to. Ledisa's catalog (NAD+, Sleep, Energy) is one bundle away from this play.
The direct rivals' YouTube layer is affiliate reviews, not brand-owned video (Kind Patches is the lone exception, and even it leads on TikTok). Compliant, brand-owned YouTube/Demand Gen creative is effectively uncontested for everyone else. Full campaign design on the Demand Gen page.
Publish Ledisa-owned comparison/review content against the unstable funnel brands whose searchers are actively typing "scam" — capture them at the moment of doubt instead of only paying CPC for their brand terms.
| Brand | Positioning | Price | Promo depth | Search presence | Video / social | Threat |
|---|---|---|---|---|---|---|
| Kind Patches | "Berberine (Upgraded GLP-1)" lifestyle brand | $15 / sub $12.75 | B2G1 + 50% bundles | Owns "berberine patches"; retail pages rank | TikTok Shop leader; active Meta ads; no YouTube | Very high |
| Patched | Pivoting GLP-1 → "Slim Control"; variants sold out | $39.99 (50% off) | 50% | Weak | None observed | Fading |
| Gentle Patches | "Berberine (formerly GLP-1)" | n/a | 70% / B3G2 | Seeded newswire advertorials | Affiliate YouTube only | Medium |
| Purisaki | Soft "daily balance" berberine | ~$31 | 10% first order | 5+ clone domains | ~17 Meta ads via white-label pages | Medium |
| Ozempatch / RejuvaCare | "Reactivate GLP-1 — no diet or exercise" | n/a | 70% | 6+ clone domains; runs "Lean Patch" too | Not observed | Medium* |
| Lipovia | "+13% GLP-1, clinically proven" + scarcity stack | n/a | Countdown / scarcity | Parasite SEO on .edu domains | Affiliate YouTube | Medium |
| The Good Patch · Barrière · NUTRIPATCH | Mainstream wellness patches — no GLP-1 SKU | $12–18 | Light | Strong retail/press | Established | Low — adjacent |
*Medium commercial threat, extreme enforcement exposure. Full source log (every page fetched,
every blocked source, every not-found item) in the working file competitor_analysis.md; key sources:
brand sites fetched Jun 11 2026, Media Matters (Sep 2025), FDA/FTC public records, Meta Ad Library via browser.